Trade GRI stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
GRI Bio, Inc. (GRI) is trading at US$1.90, down 0.52% today as of Oct 6, 16:00 EDT. The company has a market capitalisation of US$3.61M. Over the past 52 weeks, GRI has traded between US$1.36 and US$64.12. On Syfe you can trade GRI with $0 commission and add it to your watchlist.
| Previous close | US$1.91 |
|---|---|
| Market cap | US$3.61M |
| 52-week range | US$1.36 – US$64.12 |
| Volume | 18.16K |
| Exchange | US |
GRI Bio, Inc.
GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
Year: 2023
GRI Bio Receives FDA Orphan Drug Designation for GRI-0621 to Treat Idiopathic Pulmonary Fibrosis
Jun 18, 12:48 PM · MT Newswires
GRI Bio, Inc. (GRI) stock is trading at US$1.90, -0.52% from the previous close of US$1.91.
The market cap for GRI Bio, Inc. (GRI) stock is approximately US$3.61M.
The 52-week high for GRI Bio, Inc. (GRI) stock is US$64.12.
The 52-week low for GRI Bio, Inc. (GRI) stock is US$1.36.
GRI Bio, Inc. (GRI) does not currently pay a dividend.
Stay on top of GRI
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
